Clinical Trial Detail

NCT ID NCT01281176
Title High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

Advanced Solid Tumor

Therapies

Carboplatin + Vorinostat

Paclitaxel + Vorinostat

Age Groups: senior adult

No variant requirements are available.